Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/10/2020
SIETES contiene 93133 citas

 
 
<< anterior 21 a 40 de 143 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Moyle G, Boffito M. Unexpected drug interactions and adverse events with antiretroviral drugs. Lancet 2004;364:8-10. [Ref.ID 70638]
22.
Ruxrungtham K, Boyd M, Bellibas E, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, Patel I H. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004;44:793-802. [Ref.ID 70519]
25. Cita con resumen
Anónimo. Drug interactions with grapefruit juice. Med Lett Drugs Ther 2004;46:2-4. [Ref.ID 68641]
26. Cita con resumen
Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-11. [Ref.ID 68473]
27.
Clavel F, Jance AJ. HIV drug resistance. N Engl J Med 2004;350:1023-35. [Ref.ID 68220]
28. Cita con resumen
Teira R, Cámara MM, Escobar A, Muñoz P, López De Munain J, Santamaría JM. Ensayo clínico comparativo, aleatorizado y abierto sobre la efectividad de indinavir, ritonavir y saquinavir. Med Clin (Barc) 2003;121:532-4. [Ref.ID 67964]
29.
Plosker G L, Scott LJ. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 2003;63:1299-324. [Ref.ID 66496]
30.Tiene citas relacionadas Cita con resumen
Mawson AR. Effects of antiretroviral therapy on occurrence of pre-eclampsia. Lancet 2003;361:347-8. [Ref.ID 64915]
31.
Galli M, Cozzi-Lepri A, Ridolfo A L, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Vacarezza M, Vullo V, Cargnel A, Minoli L, Coronado O, Giacometti A, Antinori A, Antonucci G, d'Arminio Monforte A, Moroni M, for the LipoICoNa Study. Incidence of adipose tissue alterations in first-line antiretroviral therapy. The LipoICoNa Study. Arch Intern Med 2002;162:2621-8. [Ref.ID 64397]
32.
Avi Lemberg D, Palasanthiran P, Goode M, Ziegler JB. Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf 2002;25:973-91. [Ref.ID 63888]
33.
Pfiseter M, Labbé L, Lu J-F, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB, and the AIDS Clinical Trial Group Protocol 398 Investigators. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002;72:133-41. [Ref.ID 62999]
34.Tiene citas relacionadas
Trachtenberg JD, Sande MA. Emerging resistance to nonucleoside reverse transcriptase inhibitors. A warning and a challenge. JAMA 2002;288:239-41. [Ref.ID 62741]
35.Tiene citas relacionadas
Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos C J, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8. [Ref.ID 62735]
36.Tiene citas relacionadas
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wehat LJ, Mitsuyasu R T, Gulick RM, Valentine FT, Aberg JA, Rogers M D, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW, for the AIDS Clinical Trials Group 398 Study Team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure. A randomized trial. JAMA 2002;288:169-80. [Ref.ID 62734]
37.Tiene citas relacionadas
Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002;346:1879-91. [Ref.ID 62519]
38. Cita con resumen
Anónimo. Brazil to produce two antiretrovirals. Scrip 2002;2749:18. [Ref.ID 62115]
39.
Grub S, DeLora P, Lüdin E, Duff F, Fletcher CV, Brundage RC, Kline MW, Calles NR, Schwarzwald H, Jorga K. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2002;71:122-30. [Ref.ID 61855]
40.
Anónimo. Drugs for HIV infection. Med Lett Drugs Ther 2001;43:103-8. [Ref.ID 60942]
Seleccionar todas
 
<< anterior 21 a 40 de 143 siguiente >>